Form 4: Beam Therapeutics Director Carole Ho Reports Stock Option Grant

Director Carole Ho of Beam Therapeutics Inc. reports the acquisition of stock options.

Summary

• On June 5, 2024, Carole Ho, a director of Beam Therapeutics Inc., reported the acquisition of 23,114 stock options.
• The options have an exercise price of $24.49.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the next annual meeting, contingent upon continued service on the board.
• The expiration date for these options is June 5, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative. It's a neutral event in terms of sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term growth.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options as part of their compensation strategy for directors and key personnel.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates